AU3846395A - Compositions comprising carbazoles and cyclodextrins - Google Patents

Compositions comprising carbazoles and cyclodextrins

Info

Publication number
AU3846395A
AU3846395A AU38463/95A AU3846395A AU3846395A AU 3846395 A AU3846395 A AU 3846395A AU 38463/95 A AU38463/95 A AU 38463/95A AU 3846395 A AU3846395 A AU 3846395A AU 3846395 A AU3846395 A AU 3846395A
Authority
AU
Australia
Prior art keywords
carbazoles
cyclodextrins
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38463/95A
Inventor
Jean Louis Mesens
Jozef Peeters
Peter Putteman
Herman Maria Jozef Van Cauteren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU3846395A publication Critical patent/AU3846395A/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU38463/95A 1994-11-07 1995-10-31 Compositions comprising carbazoles and cyclodextrins Abandoned AU3846395A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94203242 1994-11-07
EP94203242 1994-11-07
PCT/EP1995/004295 WO1996014090A1 (en) 1994-11-07 1995-10-31 Compositions comprising carbazoles and cyclodextrins

Publications (1)

Publication Number Publication Date
AU3846395A true AU3846395A (en) 1996-05-31

Family

ID=8217355

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38463/95A Abandoned AU3846395A (en) 1994-11-07 1995-10-31 Compositions comprising carbazoles and cyclodextrins

Country Status (5)

Country Link
AU (1) AU3846395A (en)
IL (1) IL115885A0 (en)
TR (1) TR199501376A2 (en)
WO (1) WO1996014090A1 (en)
ZA (1) ZA959388B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063967A1 (en) * 1998-06-05 1999-12-16 Dec Research Enhanced intra vaginal devices

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
MXPA03004347A (en) 2000-11-17 2004-05-04 Takeda Chemical Industries Ltd Novel imidazole derivatives, production method thereof and use thereof.
CA2429437A1 (en) 2000-11-20 2002-05-23 Takeda Chemical Industries, Ltd. Imidazole derivatives, process for their preparation and their use
EP1348706B1 (en) 2000-12-08 2009-08-19 Takeda Pharmaceutical Company Limited Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
AR078228A1 (en) 2009-06-26 2011-10-26 Novartis Ag CYP17 INHIBITORS
KR20120095402A (en) * 2009-10-23 2012-08-28 파나셀라 랩스, 아이엔씨. Method for treating androgen receptor positive cancers
MX345788B (en) 2010-08-04 2017-02-15 Pellficure Pharmaceuticals Inc * Combination therapy for the treatment of prostate carcinoma.
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
EA023064B1 (en) 2011-04-28 2016-04-29 Новартис Аг 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
WO2014158875A1 (en) 2013-03-14 2014-10-02 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
AU2015314772B2 (en) 2014-09-12 2020-02-27 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
EP3528799A1 (en) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310635D0 (en) * 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063967A1 (en) * 1998-06-05 1999-12-16 Dec Research Enhanced intra vaginal devices

Also Published As

Publication number Publication date
ZA959388B (en) 1997-05-06
WO1996014090A1 (en) 1996-05-17
IL115885A0 (en) 1996-01-31
TR199501376A2 (en) 1996-06-21

Similar Documents

Publication Publication Date Title
AU3641597A (en) Methods and compositions comprising r-ibuprofen
AU3767097A (en) Shampoo compositions and method
AU7323294A (en) Perfluoroelastomeric compositions and methods
AU7564694A (en) Erection-inducing methods and compositions
AU2517397A (en) Document of value
AU2825597A (en) Elastomer compositions and methods
AU5522798A (en) Water-responsive polymer compositions and method of making the same
AU4261697A (en) Compounds and methods
EP0690494A3 (en) Connection and build-up-process for multi-chip-modules
AU4266596A (en) Composition and use
AU2349399A (en) R-lansoprazole compositions and methods
AU3308195A (en) Antihypertriglyceridemic composition
AU2972597A (en) Compositions and uses thereof
AU3846395A (en) Compositions comprising carbazoles and cyclodextrins
AU5157898A (en) Hnf3delta compositions
AU4425696A (en) Polymerizable compounds and compositions
AU9301998A (en) Composition and methods using galectin-1
AU4876397A (en) Insecticidal compositions and methods
AU1939895A (en) Enzymatic debridement compositions and methods
AU1841195A (en) 1-beta -methyl-carbapenem, compositions containing same and methods of use
AU7525496A (en) Methods and compositions comprising glut-2 and glut-2 chimeras
AU1129697A (en) Modified polyalkadiene-containing compositions
AU6619596A (en) Compositions
AUPO982097A0 (en) Methods and compositions for use therein
AU1468797A (en) Ghrh-rp compositions and methods